Q-omics provides the consensus-scored GCNT1P5 profile across patient tissues and cancer cell-line models. GCNT1P5 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, GCNT1P5 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, GCNT1P5 RNA expression shows 6,443 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KICH, and STAD as cancer lineages where GCNT1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCNT1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCNT1P5 survival associations across molecular data types. GCNT1P5 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCNT1P5 RNA expression–survival associations across cancer types. High GCNT1P5 expression shows unfavorable associations in TGCT, LUSC, LIHC and LAML, but favorable associations in BLCA and ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for GCNT1P5 RNA expression.
This table summarizes GCNT1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GCNT1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCNT1P5 shows lower tumor expression in KICH. The KICH box plot shows higher GCNT1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .003).
This table shows molecular features associated with GCNT1P5 in patient tissues and cancer cell lines. In patient samples, GCNT1P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
